Jazz Pharmaceuticals PLC (JAZZ)
Return on equity (ROE)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 414,832 | 79,954 | -86,514 | -156,287 | -224,060 | -18,687 | -51,872 | -449,853 | -329,668 | -160,903 | 40,164 | 518,281 | 238,616 | 179,194 | 133,236 | 280,333 | 523,367 | 608,845 | 655,885 | 486,308 |
| Total stockholders’ equity | US$ in thousands | 3,737,000 | 3,489,370 | 3,525,680 | 3,335,040 | 3,085,730 | 2,745,190 | 3,200,780 | 3,608,490 | 3,965,190 | 3,938,480 | 4,131,490 | 3,797,690 | 3,659,740 | 3,377,200 | 3,141,800 | 2,808,500 | 3,110,980 | 3,054,400 | 2,983,430 | 2,730,450 |
| ROE | 11.10% | 2.29% | -2.45% | -4.69% | -7.26% | -0.68% | -1.62% | -12.47% | -8.31% | -4.09% | 0.97% | 13.65% | 6.52% | 5.31% | 4.24% | 9.98% | 16.82% | 19.93% | 21.98% | 17.81% |
December 31, 2023 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $414,832K ÷ $3,737,000K
= 11.10%
To analyze Jazz Pharmaceuticals plc's return on equity (ROE) performance based on the provided data table, we observe a fluctuating trend in ROE over the eight quarters displayed. In Q4 2023, the ROE stood at 11.10%, showing a significant improvement compared to the previous quarters. This increase indicates that the company generated a higher return for its shareholders relative to its equity base during this period.
However, prior to this improvement, Jazz Pharmaceuticals' ROE had been relatively subdued, with negative ROE figures in Q1 2023, Q2 2023, and Q4 2022. These negative values suggest that the company was not efficiently utilizing its shareholders' equity to generate profits during those quarters.
It is essential to note that the company's ROE performance was volatile, as evidenced by the fluctuating values across the quarters. This fluctuation could be attributed to various factors such as changes in profitability, equity structure, or financial leverage.
Overall, Jazz Pharmaceuticals plc's ROE performance indicates a mix of positive and negative trends, highlighting the need for further analysis to understand the underlying factors influencing the company's profitability and shareholder value creation.
Peer comparison
Dec 31, 2023